NASA's Johnson Space Center Approves Grant for Nanobacterial Research

TAMPA, Fla.--(BUSINESS WIRE)--Oct. 4, 2005--Nanobac Life Sciences, Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announced today a $95,000 grant awarded by CDDF to David S. McKay, Astromaterials Research and Exploration Science Directorate at NASA's Johnson Space Center, for Calcification and Biomineralization and Nanobacteria Research.

The grant will be used to characterize and understand Nanobacteria's calcification and biomineralization properties and focus on nanobacteria as a model for health-threatening calcification and as a model for fossil biosignatures in a search for life. New collaborations are anticipated with JSC Bio-Medical groups, UT Medical Systems, Nanobac Life Sciences (Nanobac), and others. Current theory is that the complex calcification forms produced by these nano-particles not only may have undesirable effects on human health, but may also provide new insights into how fossils form in nature. One goal of NASA's new exploration program is to search for evidence for life, such as fossils on Mars and other planetary bodies.

"This grant will allow for groundbreaking growth in the area of geomedicine," said Neva Ciftcioglu, PhD, Nanobac's Director of Science. "Calcified Nano-particles (CNPs) or nanobacteria, are an example of biomineralization that has been linked to many health problems. This money will allow for expanded research in the area of kidney stones and characterization of CNPs and provide new tools for the search for life beyond earth."

"We are excited that the CDDF acknowledged our preliminary findings in the nanobacteria calcification/biomineralization field and decided to fund our future studies," stated David McKay, PhD, Chief Scientist for Astrobiology in the Astromaterials Research and Exploration Science Directorate at NASA's Johnson Space Center. "Nanobacteria as a model for health-threatening calcification diseases will allow us to merge geology with health care and I am eager to head this multi-disciplinary team."

About Nanobac Life Sciences

Nanobac Life Sciences, Inc. is a broad-based life science company that discovers, develops, manufactures, and markets a range of products and services to improve people's health through the detection and treatment of Calcifying Nano-Particles (CNPs), otherwise known as "nanobacteria." The Company's pioneering research is establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease.

Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for the detection of Calcifying Nano-Particles. IVD products include the NanoCapture(TM) and Nano-Sero(TM) ELISA assays and the Nano-Vision(TM) line of antibodies and reagents. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. Nanobac's Drug Discovery and Development efforts are focused on developing new and existing compounds that effectively inhibit, destroy or neutralize CNPs. The Company also markets Dietary Supplements through its subsidiary, Nanobac Sciences, LLC.

Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobac.com .

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.